688351 Shanghai Microport Ep Medtech
- 23.89
- +0.44+1.88%
Shanghai Microport Ep Medtech News
Cathay Pacific Junan: The valuation level of the normalized mining industry is expected to rise
The Zhitong Finance App learned that Guotai Junan released a research report saying that in recent years, the quality of collection has been improved and expanded. Along with this, the design of collection rules has been continuously improved, and the results are more moderate and predictable. The results of this joint China Mining contract renewal have provided further verification. As the negative effects of traditional product collection are gradually clarified, emerging varieties are rapidly being admitted to hospital through collection. The number of surgeries is expected to continue to grow under the combined impetus of factors such as an aging population, increased public health awareness, and more mature procedures. The high-value consumables industry is also expected to continue to flourish on a new base, and the industry's valuation level is expected to rise. Maintain Elken Healthcare (0178
Microelectronic Physiology (688351.SH): Net profit of 4.169 million yuan in the first quarter
On April 25, Ge Longhui (688351.SH) released its first quarter report. Operating revenue was 89.15 million yuan, up 71.01% year on year, net profit of 4.169 million yuan, after deducting non-net loss of 1.35 million yuan, and basic earnings per share of 0.0089 yuan.
Shanghai MicroPort EP MedTech Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, Shanghai MicroPort EP MedTech Co., Ltd. (SHSE:688351) last week released its latest full-year, and things did not turn out so great for shareholders. Results showed a clear ear
Microelectrophysiology (688351.SH): net profit of 5.6885 million yuan in 2023, up 85.17% year on year
On March 29, Ge Longhui (688351.SH) released its 2023 annual report. Operating revenue for the reporting period was 329 million yuan, up 26.46% year on year; net profit attributable to shareholders of listed companies was 5.6885 million yuan, up 85.17% year on year; basic earnings per share were 0.0121 yuan.
Earnings Miss: Shanghai MicroPort EP MedTech Co., Ltd. Missed EPS By 69% And Analysts Are Revising Their Forecasts
Shanghai MicroPort EP MedTech Co., Ltd. (SHSE:688351) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Results showed a clear earnings miss, with CN¥32
Shanghai MicroPort EP MedTech Co., Ltd.'s (SHSE:688351) Price In Tune With Revenues
Shanghai MicroPort EP MedTech Co., Ltd.'s (SHSE:688351) price-to-sales (or "P/S") ratio of 36.6x may look like a poor investment opportunity when you consider close to half the companies in the Medica
Microelectronic Physiology (688351.SH) Performance Report: 2023 net profit of 5.4698 million yuan, up 84.06% year on year
On February 26, Ge Longhui (688351.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 329 million yuan, an increase of 26.46% over the previous year; net profit attributable to the owners of the parent company was 5.4698 million yuan, an increase of 84.06% over the previous year.
Ping An Securities: Demand in the electrophysiology industry is strong, and there is plenty of room for domestic alternatives
The Zhitong Finance App learned that Ping An Securities released a research report saying that demand in the electrophysiology industry is strong, the number of surgeries is expected to maintain a rapid growth trend, and there is plenty of room for domestic alternatives. However, with microelectrophysiology high-density calibration catheters, pressure-sensing radiofrequency ablation catheters, microelectrophysiology, Kangfeng biological cryofrequency ablation systems, and the Jinjiang Electronic Pulse Field Ablation System successively obtained NMPA registration and listing, domestic production is about to break the market. It is recommended to focus on high-quality domestic manufacturers with perfect product layout and high equipment installed capacity, such as Microelectrophysiology (688351.SH) and Huitai Medical (688617.SH). Ping An Securities views such as
Microelectrophysiology (688351.SH): 2023 net profit pre-increased 68.25% to 101.90%
On January 30, Ge Longhui (688351.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, net profit attributable to owners of the parent company is expected to be 5 million yuan to 6 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will increase RMB 2.082 million to RMB 3,028,200, an increase of 68.25% to 101.90% over the previous year. Net profit attributable to owners of the parent company after deducting non-recurring profit and loss is -36.5 million yuan to -35 million yuan.
MicroPort EP Medtech's Columbus Cardiac Mapping System Enters EU Market
Shanghai MicroPort EP Medtech (SHA:688351) will be allowed to market the Columbus three-dimensional cardiac electrophysiological mapping system in the European Union after obtaining the region's Medic
Microelectrophysiology (688351.SH): Columbus 3D cardiac electrophysiological measurement system obtained EU MDR certification
Zhitong Finance App News, Microelectrophysiology (688351.SH) announced that the company's product, the fourth-generation Columbus 3D Cardiac Electrophysiological Measurement System, recently obtained the EU Medical Device Regulation (“MDR”) certification. The fourth-generation Columbus 3D cardiac electrophysiological labeling system has obtained EU MDR certification and entered the EU market for sale. It will further promote the internationalization process of the company's products, continuously enhance the company's brand awareness overseas, and have a positive impact on the company's expansion into overseas markets.
Microelectrophysiology (688351.SH): The transfer price in this inquiry is 20.24 yuan/share
On January 15, Ge Longhui (688351.SH) announced that after consulting with institutional investors, the initial confirmed transfer price was 20.24 yuan/share, which is 90.08% of the closing price of 22.47 yuan/share on the current inquiry transfer pricing date (that is, January 15, 2024). The shares to be transferred in this inquiry have been fully subscribed. It has been initially determined that there are 12 transferees, and the total number of shares to be transferred is 6,120,000 shares.
Shanghai Yuheng, a shareholder of Microelectronics Physiology (688351.SH), plans to transfer 1.3% of the company's shares in an inquiry
Microelectronic Physiology (688351.SH) disclosed the shareholder inquiry transfer plan. The shareholders who intend to participate in the inquiry transfer are listed above...
Statutory Earnings May Not Be The Best Way To Understand Shanghai MicroPort EP MedTech's (SHSE:688351) True Position
Shanghai MicroPort EP MedTech Co., Ltd.'s (SHSE:688351) stock rose after it released a robust earnings report. Despite the strong profit numbers, we believe that there are some deeper issues which in
Shanghai MicroPort EP MedTech Co., Ltd.'s (SHSE:688351) Share Price Matching Investor Opinion
You may think that with a price-to-sales (or "P/S") ratio of 34.8x Shanghai MicroPort EP MedTech Co., Ltd. (SHSE:688351) is a stock to avoid completely, seeing as almost half of all the Medical Equipm
Microelectronics Physiology (688351.SH) released the first three quarter results, with net profit of 1.52 million yuan, an increase of 325.36% over the previous year
Microelectronics Physiology (688351.SH) disclosed the report for the third quarter of 2023. In the first three quarters, the company achieved revenue 2...
Microelectronics Physiology (688351.SH): The ban on 25 million restricted shares was lifted on September 18
Glonghui September 8: Microelectronics Physiology (688351.SH) announced that the number of restricted shares currently listed and in circulation is 24.999.97 million shares, and the listing and circulation date is September 18, 2023.
Microelectrophysiology (688351.SH): The single-use pressure-monitoring magnetic positioning radiofrequency ablation catheter has obtained EU MDR certification and British MDR certification
Glonghui, August 31 | Microelectrophysiology (688351.SH) announced that the company's single-use pressure-monitoring magnetic positioning radiofrequency ablation catheter recently obtained the EU Medical Device Regulation (“MDR”) certification certificate and the British Medical Device Regulation MDR certification certificate. The single-use pressure-monitoring magnetic positioning radiofrequency ablation catheter is suitable for intracardiac electrophysiological labeling. When used in conjunction with a radiofrequency ablation instrument, it can be used for cardiac ablation; when used in conjunction with the Columbus 3D electrophysiological labeling system, it can provide real-time measurement of pressure at the contact point between the catheter tip and the heart wall and location information.
Microelectrophysiology (688351.SH) plans to increase capital of 52.9412 million yuan to Shangyang Medical to improve the PFA field research and development bureau
Microelectrophysiology (688351.SH) announced that the company intends to cooperate with the related party Shanghai Shangyang Medical Technology Co., Ltd. (“Shangyang...
31.1698 million restricted shares of Microelectronics Physiology (688351.SH) will be listed and distributed on September 1
Microelectronics Physiology (688351.SH) announced that the total number of restricted shares currently listed and in circulation by the company is 31.1698 million...
Analysis
Price Target
No Data
